Top Markets
Coin of the day
Tricida, Inc. Tricida, Inc.

Tricida, Inc.

TCDA
Rank in Stocks #35026
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the... Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Share Price
$0.108
Last synced: 2023-01-23
Market Cap
$4.56M
Change (1 day)
-10.00%
Change (1 year)
0.00%
Country
US
Trade Tricida, Inc. (TCDA)

Category

P/S ratio for Tricida, Inc. (TCDA)
P/S ratio as of 2026 TTM: 0
According to Tricida, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Tricida, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE